Skip to main content
Corey Cutler, MD, Oncology, Boston, MA

Corey S Cutler MD

Hematologic Oncology


Associate Professor, Medicine-Brigham & Women's Hospital, Harvard Medical

Join to view full profile
  • 44 Binney Streetd1b30Danafarber Cancer InstituteBoston, MA 02115

  • Phone+1 617-632-5946

  • Fax+1 617-632-5168

Dr. Cutler is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineClass of 1996
  • McGill University Faculty of Medicine
    McGill University Faculty of MedicineMD, Medicine, 1991 - 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • MA State Medical License
    MA State Medical License 1999 - 2028
  • VT State Medical License
    VT State Medical License 2023 - 2026
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
  • CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017

Publications & Presentations

PubMed

Abstracts/Posters

  • Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
    Corey Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Development of HHV-6-Specific Immunity after Cord Blood Transplantation in
    Corey S. Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity
    Corey Cutler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • 'The Evolving Treatment Landscape for Patients with GvHD: More Options, More 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • 'Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and 
    60th American Society of Hematology Annual Meeting - 11/30/2018
  • Highlights of ASH® San Diego, CA 
    American Society of Hematology (ASH), San Diego, California - 1/18/2013

Press Mentions

  • Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Recognized for Exceptional Outcomes in Donor Stem Cell Transplants
    Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Recognized for Exceptional Outcomes in Donor Stem Cell TransplantsDecember 17th, 2025
  • Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
    Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025
  • FDA Approves Treatment for Chronic Graft Versus Host Disease
    FDA Approves Treatment for Chronic Graft Versus Host DiseaseSeptember 6th, 2024

Grant Support

  • Mechanisms and Therapy of Chronic Graft-vs.-Host DiseaseDANA-FARBER CANCER INST2022–2027

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: